South Street Advisors’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-24,537
Closed -$1.36M 81
2025
Q3
$1.36M Sell
24,537
-38,829
-61% -$2.27M 0.18% 46
2025
Q2
$4.37M Sell
63,366
-110,635
-64% -$7.53M 0.65% 36
2025
Q1
$12.1M Buy
174,001
+6,840
+4% +$565K 1.98% 23
2024
Q4
$14.4M Sell
167,161
-19,370
-10% -$2.09M 2.2% 20
2024
Q3
$22.2M Sell
186,531
-44,988
-19% -$6M 3.37% 8
2024
Q2
$33M Sell
231,519
-3,209
-1% -$425K 5.01% 4
2024
Q1
$30.1M Sell
234,728
-5,099
-2% -$607K 4.81% 4
2023
Q4
$24.8M Sell
239,827
-943
-0.4% -$93.3K 4.64% 5
2023
Q3
$21.9M Buy
240,770
+2,042
+0.9% +$180K 4.4% 4
2023
Q2
$19.3M Sell
238,728
-66,478
-22% -$5.43M 3.83% 6
2023
Q1
$24.3M Buy
305,206
+188
+0.1% +$13.3K 4.98% 3
2022
Q4
$20.6M Sell
305,018
-7,716
-2% -$452K 4.56% 2
2022
Q3
$15.6M Sell
312,734
-4,710
-1% -$252K 3.84% 6
2022
Q2
$17.7M Buy
317,444
+132,610
+72% +$7.36M 4.03% 2
2022
Q1
$10.3M Buy
+184,834
New +$9.49M 1.94% 26

Other funds holding NVO

South Street Advisors's NVO Position: Q4 2025 in Review

South Street Advisors sold out of Novo Nordisk (NVO) in Q4 2025, closing a stake of 24,537 shares — an estimated $1.36M sold.

South Street Advisors first reported a position in NVO in Q1 2022 and held it in 15 quarters. The position peaked at $33M in Q2 2024. 1,414 funds tracked by Wall St. Rank hold NVO as of Q4 2025.

  • South Street Advisors reported no remaining Novo Nordisk position as of Q4 2025 after selling out during the quarter.
  • South Street Advisors sold 24,537 Novo Nordisk shares in Q4 2025, an estimated $1.36M.
  • South Street Advisors first reported a position in Novo Nordisk in Q1 2022 and held it in 15 quarters.
  • South Street Advisors's Novo Nordisk position peaked at $33M in Q2 2024.
  • 1,414 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2025.

Based on South Street Advisors's 13F filing for Q4 2025, filed 10 Feb 2026.